Managing directors/CEOs of foreign firms in India drew higher remuneration in 2019-20 versus the previous year and overall earnings of peers at Indian firms continued to be way higher in general. CEO-to-employee pay ratios remains stark, reaching over 550 in one case.

Yumanity goes public by merging with Proteostasis; it is accelerating its Parkinson’s program because of mouse model data showing disease-modifying potential. Proteostasis will out-license its CF assets.

Deal Snapshot: The $445m Cerevel gains will help as it plans to have at least six programs in the clinic within the next year. CEO Tony Coles will head up a public firm for the first time since Amgen bought Onyx. 

The company previously cut 2020 revenue expectations by $2.5bn, including $1.7bn for pharma products. Keytruda’s dominance and portfolio diversification also may dominate second quarter call.